S. Seidu Et Al. , "Benefits and harms of sodium-glucose co-transporter-2 inhibitors (SGLT2-I) and renin-angiotensin-aldosterone system inhibitors (RAAS-I) versus SGLT2-Is alone in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials," ENDOCRINOLOGY DIABETES & METABOLISM , vol.5, no.1, 2022
Seidu, S. Et Al. 2022. Benefits and harms of sodium-glucose co-transporter-2 inhibitors (SGLT2-I) and renin-angiotensin-aldosterone system inhibitors (RAAS-I) versus SGLT2-Is alone in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. ENDOCRINOLOGY DIABETES & METABOLISM , vol.5, no.1 .
Seidu, S., Kunutsor, S. K., Topsever, P., & Khunti, K., (2022). Benefits and harms of sodium-glucose co-transporter-2 inhibitors (SGLT2-I) and renin-angiotensin-aldosterone system inhibitors (RAAS-I) versus SGLT2-Is alone in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. ENDOCRINOLOGY DIABETES & METABOLISM , vol.5, no.1.
Seidu, Samuel Et Al. "Benefits and harms of sodium-glucose co-transporter-2 inhibitors (SGLT2-I) and renin-angiotensin-aldosterone system inhibitors (RAAS-I) versus SGLT2-Is alone in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials," ENDOCRINOLOGY DIABETES & METABOLISM , vol.5, no.1, 2022
Seidu, Samuel Et Al. "Benefits and harms of sodium-glucose co-transporter-2 inhibitors (SGLT2-I) and renin-angiotensin-aldosterone system inhibitors (RAAS-I) versus SGLT2-Is alone in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials." ENDOCRINOLOGY DIABETES & METABOLISM , vol.5, no.1, 2022
Seidu, S. Et Al. (2022) . "Benefits and harms of sodium-glucose co-transporter-2 inhibitors (SGLT2-I) and renin-angiotensin-aldosterone system inhibitors (RAAS-I) versus SGLT2-Is alone in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials." ENDOCRINOLOGY DIABETES & METABOLISM , vol.5, no.1.
@article{article, author={Samuel Seidu Et Al. }, title={Benefits and harms of sodium-glucose co-transporter-2 inhibitors (SGLT2-I) and renin-angiotensin-aldosterone system inhibitors (RAAS-I) versus SGLT2-Is alone in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials}, journal={ENDOCRINOLOGY DIABETES & METABOLISM}, year=2022}